Showing results (81-90 of 92) with videos related to
Sort By:
Pageof 10
Journal of Immunology (Baltimore, Md. : 1950)|May 6, 2008
The chemokine receptor CXCR3 is degraded following internalization and is replenished at the cell surface by de novo synthesis of receptorAndrea Meiser, Anja Mueller, Emma L Wise, et al.Journal of Immunology (Baltimore, Md. : 1950)|November 19, 2013
The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancerKousaku Mimura, Kensuke Shiraishi, Anja Mueller, et al.Cellular and Molecular Life Sciences : CMLS|November 5, 2022
Induction of pulmonary HLA-G expression by SARS-CoV-2 infectionBarbara Seliger, Simon Jasinski-Bergner, Chiara Massa, et al.Cancers|August 7, 2021
Distinct Molecular Mechanisms of Altered HLA Class II Expression in Malignant MelanomaStefanie Meyer, Diana Handke, Anja Mueller, et al.Cancer Immunology, Immunotherapy : CII|August 4, 2019
Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapyMichael Friedrich, Simon Jasinski-Bergner, Maria-Filothei Lazaridou, et al.Oncoimmunology|December 2, 2024
Blood immune profiling of Ethiopian patients with breast cancer highlights different forms of immune escapeMeron Yohannes, Chiara Massa, Zelalem Desalegn, et al.Frontiers in Immunology|January 11, 2020
Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome DisplayStina L Wickström, Tanja Lövgren, Michael Volkmar, et al.Cancers|June 2, 2021
Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study)Philip Zeuschner, Sebastian Hölters, Michael Stöckle, et al.Journal for Immunotherapy of Cancer|November 17, 2020
Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBCChiara Massa, Thomas Karn, Carsten Denkert, et al.Cancer Research|June 29, 2017
Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ SignalingMarco Donia, Katja Harbst, Marit van Buuren, et al.Pageof 10